A number of cyclic and linear peptides containing various combinations of amino acids were evaluated for their Src kinase inhibitory potency. Among all the peptides, cyclic decapeptide C[RW] 5 containing alternative arginine (R) and tryptophan (W) residues was found to be the most potent Src kinase inhibitor. C[RW] 5 showed higher inhibitory activity (IC50 = 2.8 µM) than C[KW] 5 , L(KW) 5 , C [RW] 4 , and C[RW] 3 with IC 50 values of 46.9, 69.1, 21.5, and 25.0 µM, respectively, as determined in a fluorescence intensity-based assay. Thus, the cyclic nature, the presence of arginine, ring size, and the number of amino acids in the structure of the peptide were found to be critical in Src kinase inhibitory potency. The IC 50 value of C[RW] 5 was found to be 0.8 µM in a radioactive assay using [γ-32 P]-ATP and polyE 4 Y as the substrate. C[RW] 5 was a non-competitive Src kinase inhibitor, showing approximately 4-fold more selectivity towards Src than Abl.
Protein tyrosine kinases (PTKs) are enzymes that catalyze the transfer of the γ-phosphate group from ATP to the hydroxyl group in tyrosine residues in proteins. Src family kinases (SFKs) including Src, Yes, Fyn, Fgr, Hck, Lck, Blk, Lyn, and Frk are non-receptor tyrosine kinases that play critical roles in several cellular signaling pathways. SFKs contain five distinct functional domains from the N-to C-terminals, including fatty acid acylation, Src homology 3 (SH3), Src homology 2 (SH2), kinase (containing ATP and substrate binding sites), and a C-terminal regulatory domain. 1 Src contributes a significant role in cell proliferation, differentiation, and motility in many normal cell lines. 2 Overexpression of Src kinase is observed in different types of cancer cells. 3 Thus, the design of potent Src kinase inhibitors has become a subject of major interest in drug discovery. 4, 5 Most of the attention has been on designing Src kinase inhibitors through blocking Src-dependent substrate phosphorylation. The kinase domain inhibitors are designed to inhibit the binding of ATP (ATP binding site inhibitors) 6, 7 or the protein substrate (substrate binding site inhibitors). [8] [9] [10] © 2013 Elsevier Ltd. All rights reserved.
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Supplementary data Supplementary data including cyclic and linear peptide synthetic procedures and additional supporting data including mass spectra can be found in the online version of this article. In general, linear peptides adopt highly flexible conformations in a solution that could lead to weak interactions with the desired target. The optimized linear peptides usually show PTK inhibitory potency in the micromolar range. 11 Moreover, linear peptides have limited stability and low bioavailability because of proteolytic degradation by natural cellular protease. Thus, further structural modification is required to enhance the stability, potency, and selectivity of the linear peptides.
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Cyclization strategy has been shown to be effective in developing more potent and stable peptidic and peptidomimetic agents. [12] [13] [14] [15] Cyclization of peptides has been commonly used to reduce the conformational freedom of the peptides. Introducing conformational constraints in peptides make them more stable towards proteases. In addition, cyclization often results in higher receptor binding affinity towards specific receptors possibly by decreasing unfavorable entropic effects. 16 For example, G7-18NATE peptide (cyclo-[CH 2 COWFEGYDNTFPC]-amide) is a non-phosphorylated tyrosine-containing peptide that was developed to target specifically the SH2 domain of the growth factor receptor bound protein 7 (Grb7). 17 We have previously reported the synthesis of a number of cyclic peptides, including analogues of Ac-CIYKYY and GpYEEI as Src kinase inhibitors and Src SH2 domain binding ligands, respectively. Conformational constrained peptides of CIYKYY significantly improved the inhibitory potency of the peptides against active Src kinase when compared with the corresponding linear peptide. 18 Conformationally constrained analogs of GpYEEI also showed significantly higher binding affinity towards the Src SH2 domain. 16 However, a detailed mechanistic study of the role of hydrophobicity, charge, and amino acid sequence on their Src inhibitory potency of cyclic peptides remained elusive. In continuation of our efforts to develop new cyclic peptide scaffolds as Src kinase inhibitors, 11, 19 herein we report the design and evaluation of cyclic peptides containing charged and hydrophobic residues for potential applications as a new class of Src kinase inhibitors. The hydrophobic residues such as aromatic side chains of phenylalanine and tryptophan were expected to occupy and/or interact with a large hydrophobic pocket 19 , were synthesized by employing 9-fluorenylmethyloxycarbonyl (Fmoc)-based chemistry according to our previously reported procedure. 20 The design and selection of the cyclic peptides was based on the presence of hydrophobic (e.g., W, F, A) and charged residues (e.g., K, R, E). To investigate the role of the constrained cyclic nature of the peptide, the corresponding linear (RW) 5 5 (IC 50 = 7.1 µM)). These data suggest that the presence of arginine is required for optimal Src inhibitory activity.
In order to determine the selectivity of C[RW] 5 toward Src kinase, the IC 50 values of the peptide were ascertained in two other divergent non-receptor protein tyrosine kinases, Abl and Csk in a radioactive assay using [ -32 P]-ATP and polyE 4 Y as the substrate. Enzyme activity and inhibition were characterized using the following methods, adapted from previous work. 14, 15, 21 Csk and Src activity levels were measured from incubations with polyE4Y (1 mg/mL). CrkL (0.5 mg/mL) was used as a substrate for Abl. C[RW] 5 was dissolved in 10% DMSO/90% kinase buffer solution (KB10) and diluted in series as needed. In conclusion, a new class of cyclic peptides containing different combinations of amino acids was evaluated for Src kinase inhibitory activity. To the best of our knowledge, this is the first report of cyclic peptides containing hydrophobic and positively charged residues as Src kinase inhibitors. The combination of tryptophan and arginine showed the highest potency to inhibit the Src kinase activity compared to other peptides. The cyclic nature, ring size, and the presence of arginine and tryptophan residues were found to contribute significantly to the Src inhibitory activity. 
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Chemical structures of synthesized cyclic peptides. Chemical structures of L(RW) 5 and L(KW) 5 . 
